Page 102 - Read Online

Thonglert et al. Hepatoma Res 2023;9:40 https://dx.doi.org/10.20517/2394-5079.2023.47 Page 7 of 23

Cirrhosis: N/A
Prior treatment: surgery
35.7%
Disease status:
unresectable: 64.3%;
recurrent tumor after
surgery: 35.7%
[36] +
Ohkawa et al. 2015 Retrospective Japan iCCA 20 Treatment volume Age: median: 74 (range 55- 20.8 mo 1-yr LC 88% Median OS 27.5 Acute G3: bone
+ + +
study (curative: 12, - GTV = primary tumor 82) (range, 8.6- 2-yr LC 60% m marrow suppression 1
+ + + +
palliative:8) - CTV = GTV + (5-10) mm Sex: male: 58.3% 62.6) 3-yr LC 60% 1-yr OS 82% Late G3: biliary tract
+ +
- PTV = CTV + (5-10) mm Location: iCCA 100% 2-yr OS 61% infection 2 (No G4+)
+ +
Dose: near GI tract 60-77 Solitary lesion: 75% 3-yr OS 38%
GyE in 30-35 F; Tumor size: < 5 cm: 50%;
central tumor 72.6-79.2 5.1-9.9 cm: 41.6%; ≥ 10 cm
+
GyE in 16-22 F; others 55- 8.3%
+
60 GyE in 10 F; median Metastasis: 0%
+
dose 72.6 GyE in 22 F Cirrhosis: N/A
+
Technique: double Prior treatment: N/A
scattering
[37] +
Shimizu et al. 2019 Retrospective Japan iCCA 37 (25 Treatment volume Age: median 72 yr (44-82 37.5 mo 1-yr LC 100% Median OS 25 Acute G3+: 0
+ + +
study curatives, 12 - GTV = gross tumor yr) 2-yr LC 71.5% m Late G3 biliary tract
+ +
palliatives) - CTV = GTV + (5-10) mm Sex: male 68% 1-yr OS 66.3% infection = 3*
+ +
- PTV = CTV + (5-10) mm Solitary lesion: 88% 2-yr OS 52.4% Link to PBT unclear
Dose: Tumor size: median 4.4 cm
+
within 2 cm from the GI (range, 1.5-14)
+
tract 74 GyE in 37 F; Metastasis: 12%
+
central tumor 72.6 GyE in CP: A 80%; B 20%
+
22 F; others 66 GyE in 10 F Prior treatment: N/A
Technique: double
scattering
[38]
Hung et al. 2020 Retrospective Taiwan 30 (iCCA 18) Treatment volume Age: median 69 yr (range 16 mo (range 1-yr LC 88% Median OS 19.3 G3 dermatitis 2 (6.7%)
study GTV = gross tumor + gross 49-88) 3-36 mo) mo G3-4 duodenal/gastric
LN Sex: male 50% 1 yr OS 83% ulcer 3 (10%)
CTV = (GTV + 5 mm) + Location: iCCA 60%; eCCA 2 yr OS 32% No grade 5 toxicity
(bile duct + 5-10 mm) 30%; GB 10% RILD 2 (6.7%)
Dose: 72.6 GyE in 22 F or Solitary lesion: 83.3%
66 GyE in 10; median Tumor size: 7 cm (range
BED10 96.5 GyE (range 3.4-17.5 cm)
52.7-109.6 GyE) Metastasis: 6.7%
Technique: PS Cirrhosis: 6.7%
Recurrent disease 16.7%
Prior treatment: surgery
6.7%; radiotherapy 10%;
induction CT 56.7%
[39]
Kim et al. 2022 Retrospective Korea iCCA 47 Treatment volume Age: median 67 (45-83) 18.3 mo 1-yr LC 91.7% Median OS 21.9 G3 toxicity: BC
study - GTV = gross tumor Sex: male 68.1% (range 2.4- 2-yr LC 86.9% mo decrease: 2 (4.3%)
- ITV = GTV + movement Solitary lesion: N/A 89.9 mo) EQD2 ≥ 80 vs. < 1 yr OS 63.8% ilirubin increase 2
10
of GTV Tumor size: median 5.2 cm 80 GyE 2-yr LC 2 yr OS 42.7% (4.3%)